STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

GILD GILEAD SCIENCES INCORPORATED StockScouter® Report

4

StockScouter® Score

GILEAD SCIENCES INCORPORATED, a large cap growth company in the healthcare sector, is expected to slightly outperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive
  • The enterprise value-to-sales ratio is approximately in line with that of comparably-sized companies in the StockScouter universe. Neutral

 

Concerns

  • One or more analysts has significantly decreased quarterly earnings estimates for GILD. Negative
  • Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that large cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 60% done.
Progress: 80% done.
Low
High

Core Model Grades

D
C
C
D

Previous Ratings

8
6
3